We recently published
10 Stocks Crash as AI Glow Fades. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s worst performers.
Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 apiece after investors mimicked the recent selling of three company executives.
In separate regulatory filings on Tuesday, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that its chief executive officer (CEO), chief financial officer (CFO), and chief research and development officer (CRDO) unloaded positions in the company on August 15 and 18.
CEO Christopher Gibson, for his part, unloaded $40,390 worth of shares on August 15 at a price of $5.64. Despite the transaction, Gibson’s stake in the company remained at 954,229.
Meanwhile, CFO Ben Taylor also unloaded $11,908 worth of shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on August 15 at a price of $5.64 apiece, bringing his ownership in the company to 811,226.
CRDO Najat Khan sold shares worth $3,789 at a price of $5.64 on August 15, followed by shares amounting to $36,599 at an average price of $5.524 on August 18, 2025.
All transactions represented shares that have been withheld to satisfy tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
In the second quarter of the year, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) widened its net loss by 76 percent to $171.9 million from $97.5 million in the same period last year. Total revenues increased by 33 percent to $19.2 million from $14.4 million year-on-year.
While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the
best short-term AI stock.
